Life Biosciences Stock
| Valuation | n/a |
| Valuation Date | n/a |
| Implied Valuation | n/a |
| Last Price | $44.59 |
| 52-Week High | $44.59 |
| 52-Week Low | $6.26 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $240M1 |
| Latest Round Amount | $80M2 |
| Latest Round | Series D |
| Funding Rounds | 4 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Life Biosciences
Life Biosciences is a clinical-stage biotechnology company developing cellular rejuvenation therapies that reverse age-related disease by resetting the epigenetic code of damaged cells. Its Partial Epigenetic Reprogramming platform uses controlled expression of three Yamanaka factors (OCT4, SOX2 and KLF4) to restore older cells to a younger functional state without fully erasing cell identity. The lead candidate ER-100 is an AAV gene therapy in a Phase 1 trial for optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The company makes money by developing these prescription gene therapies for commercialization and partnering. It was co-founded by Harvard geneticist David Sinclair.
Invest in Life Biosciences
Life Biosciences is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
World First: Patient Receives High-Risk Therapy to Make Cells Young Again
ScienceAlert reports that Life Biosciences has begun dosing patients with ER-100, an experimental gene therapy designed to reverse age-related damage in retinal cells. The Phase 1 trial focuses on saf...
Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies
Life Biosciences dosed the first participant in its Phase 1 trial of ER-100, a gene therapy targeting open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies
Life Biosciences said the first participant was dosed in its Phase 1 trial of ER-100 for optic neuropathies including open-angle glaucoma and NAION. The study primarily evaluates safety and tolerabili...
Life Biosciences Secures $80 Million Series D Financing
Life Biosciences closed a fully subscribed $80 million Series D to fund its Phase 1 ER-100 trial and expand its partial epigenetic reprogramming platform. Proceeds are expected to support operations i...
David Sinclair startup Life Biosciences raises $80M for clinical test of anti-aging gene therapy
Endpoints News covers Life Biosciences' $80 million Series D and its Phase 1 gene therapy trial for vision loss. The report says total funding is now close to $240 million.
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
The FDA cleared Life Biosciences' investigational new drug application for ER-100, allowing the company to initiate a Phase 1 study in patients with open-angle glaucoma and NAION.
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
The FDA cleared Life Biosciences' IND for ER-100, allowing the first human trial of a partial epigenetic reprogramming therapy. The Phase 1 study will enroll patients with open-angle glaucoma and NAIO...
Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors
Life Biosciences appointed ophthalmology biotech veteran David Guyer to its board ahead of planned human trials of ER-100. Guyer is CEO of Merck subsidiary EyeBio and previously co-founded Eyetech Pha...
Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases
At ARDD 2025, Life Biosciences presented preclinical data suggesting its partial epigenetic reprogramming platform may help reverse optic neuropathies and metabolic liver disease (MASH). The company h...
Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS)
Life Biosciences signed an MOU with REMEDIS in Singapore to expand research on cellular rejuvenation therapies across multiple organ systems. The partnership aims to accelerate development of age-rela...
Life Biosciences Appoints Dr. Michael Ringel as Chief Operating Officer
Life Biosciences named former BCG managing director Michael Ringel as chief operating officer. The hire came as the company prepared to advance its first partial epigenetic reprogramming candidate int...
Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimat...